Regulators concerned over liver damage risk
Suggestion is that PML case was caused by previous treatment.
Phase 3 trial meets main efficacy endpoint, but disability progression stats cause concern.
US insurers are covering the treatment, despite high price.
Sales of MS and eczema drugs could top $4bn by 2022
Biotech looks for funding and long-term development partner
Success with ozanimod would justify $7.2 billion outlay for Receptos.